Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

18    Novo Nordisk    $5.3B    up 17.8%
Global revenue: $11.7B (17th); up 9.3%

R&D spend: $1.8B (16th), up 5.9%; 15.4% of rev.

Top brands: Novolog ($1.0B), Levemir ($843M), Novolog Flexpen ($779M), Victoza 3-pack ($457M), NovoSeven ($385M)

Planned launches: Degludec/DegludecPlus (diab.), rFXIII (bleeding), liraglutide (obesity), Turoctocog alfa (haem. A)

Promotional spend: $433M (14th); 8.2% of rev.

Patent expirations: N/A

The Danish diabetes giant continues to soar on North American sales of its modern insulins, in particular. As of November, the company had captured half of the total global insulin market and almost that much of the modern insulin market. Victoza, launched in 2010 for type 2 diabetes, saw meteoric growth in 2011 and became a blockbuster, but faces competition from Amylin's Bydureon and is weighing the development of a once-weekly version to fend off the challenge. The firm has high hopes for its thrice-weekly Degludec, a basal insulin that would take on Sanofi's $5-billion Lantus, and is exploring an obesity indication for Victoza, a possible gold mine. Now if only they could do something about Victoza spoke and bad press magnet Paula Deen.

Back to first page

Page 18 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?